Abstract:Comparative genomic in situ hybridization (CGH) provides a new possibility for searching genomes for imbalanced genetic material. Labeled genomic test DNA, prepared from clinical or tumor specimens, is mixed with differently labeled control DNA prepared from cells with normal chromosome complements. The mixed probe is used for chromosomal in situ suppression (CISS) hybridization to normal metaphase spreads (CGH-metaphase spreads). Hybridized test and control DNA sequences are detected via different fluorochromes, e.g., fluorescein isothiocyanate (FITC) and tetraethylrhodamine isothiocyanate (TRITC). The ratios of FITC/TRITC fluorescence intensities for each chromosome or chromosome segment should then reflect its relative copy number in the test genome compared with the control genome, e.g., 0.5 for monosomies, 1 for disomies, 1.5 for trisomies, etc. Initially, model experiments were designed to test the accuracy of fluorescence ratio measurements on single chromosomes. DNAs from up to five human chromosome-specific plasmid libraries were labeled with biotin and digoxigenin in different hapten proportions. Probe mixtures were used for CISS hybridization to normal human metaphase spreads and detected with FITC and TRITC. An epifluorescence microscope equipped with a cooled charge coupled device (CCD) camera was used for image acquisition. Procedures for fluorescence ratio measurements were developed on the basis of commercial image analysis software. For hapten ratios 4/1, 1/1 and 1/4, fluorescence ratio values measured for individual chromosomes could be used as a single reliable parameter for chromosome identification. Our findings indicate (1) a tight correlation of fluorescence ratio values with hapten ratios, and (2) the potential of fluorescence ratio measurements for multiple color chromosome painting. Subsequently, genomic test DNAs, prepared from a patient with Down syndrome, from blood of a patient with T-cell prolymphocytic leukemia, and from cultured cells of a renal papillary carcinoma cell line, were applied in CGH experiments. As expected, significant differences in the fluorescence ratios could be measured for chromosome types present in different copy numbers in these test genomes, including a trisomy of chromosome 21, the smallest autosome of the human complement. In addition, chromosome material involved in partial gains and losses of the different tumors could be mapped to their normal chromosome counterparts in CGH-metaphase spreads. An alternative and simpler evaluation procedure based on visual inspection of CCD images of CGH-metaphase spreads also yielded consistent results from several independent observers. Pitfalls, methodological improvements, and potential applications of CGH analyses are discussed.

Comparative Genomic Hybridization Technique Detects the Chromosomal Aberration in Renal Carcinoma

[Detection of Chromosomal Aberration in Sporadic Colorectal Cancer with Comparative Genomic Hybridization].

Chromosome aberration of urine exfoliated cells to diagnose bladder neoplasm by fluorescence in situ hybridization

Chromosomal Aberrations Detected by Comparative Genomic Hybridization Predict Outcome in Patients with Colorectal Carcinoma

Genome-wide Profiling of Chromosomal Aberrations in Renal Cell Carcinoma Using High-Density Single Nucleotide Polymorphism Arrays

Chromosomal Microarray Analysis in Fetuses with Congenital Anomalies of the Kidney and Urinary Tract: A Prospective Cohort Study and Meta‐analysis

Genome-Wide Profiling Of Chromosomal Alterations In Renal Cell Carcinoma Using High-Density Single Nucleotide Polymorphism Arrays

Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization.

Comparative genomic hybridization analysis on bile duct carcinoma

[Clinicopathologic Significance of Chromosomal DNA Sequence Copy Number Aberrations in Patients with Colorectal Carcinoma].

Chromosomal Alteration In Chinese Sporadic Colorectal Carcinomas Detected By Comparative Genomic Hybridization

[Detection of the Cytogenetic Aberrations in Multiple Myeloma by Using Microrray Comparative Genomic Hybridization].

Comparative Genomic Hybridization Analysis on Primary Gallbladder Carcinoma

Application of Comparative Genomic Hybridization (CGH) in the Genetic Analysis of Lymphoma

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma

Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization

Genome-wide Screening for Genomic Aberrations in Kazakh Patients with Esophageal Squamous Cell Cancer by Comparative Genomic Hybridization.

Genomic Alterations in Lung Adenocarcinomas Detected by Multicolor Fluorescence in Situ Hybridization and Comparative Genomic Hybridization

Progression Analysis of Lung Squamous Cell Carcinomas by Comparative Genomic Hybridization

Functional Genomic Analysis of Chromosomal Aberrations in a Compendium of 8000 Cancer Genomes